Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

 Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Shots:

  • Roche divulges results from three P-III studies of Tecentriq (atezolizumab) clinical development program in TNBC at the ESMO Virtual Congress 2020. The P-III IMpassion031 assessing Tecentriq + CT vs PBO + CT demonstrated improvement in pathological complete response (pCR: 57.6% vs 41.1%) in early TNBC patients
  • The P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel vs PBO + nab-paclitaxel, as a 1L treatment for patients with m-TNBC. Results: increment in 7.5mos. in median OS, no new safety concerns were identified with longer follow-up
  • Lastly, the company presented P-III IMpassion131 study assessing Tecentriq + paclitaxel vs PBO + paclitaxel, as a 1L treatment for patients with m-TNBC. The study did not meet its 1EPs of PFS in the PD-L1+ population, OS data showed a negative trend

Click here ­to­ read full press release/ article | Ref: Roche | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post